Pupillary response to tropicamide in patients with Alzheimer disease. 1996

D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
Department of Ophthalmology, School of Medicine, Emory University, Atlanta, GA 30322, USA.

OBJECTIVE To determine whether pupillary responses to dilute tropicamide could be used as a diagnostic test for Alzheimer disease (AD). The authors also investigated whether concurrent use of an oral acetylcholinesterase inhibitor (tacrine) alters the pupillary response to dilute tropicamide in patients with AD, and whether pupillary responses to dilute tropicamide differ in young versus older control subjects. METHODS Pupillary diameter and area of both eyes were measured in light and darkness, at 10-minute intervals for 40 minutes after random instillation of 0.01% tropicamide to one eye. Four groups of subjects were studied: 9 patients with AD, 10 who were treated with tacrine, 11 older control subjects, and 10 young control subjects. RESULTS Mean change in anisocoria was not significantly different among groups at any of the measurement time points. Mean percent change in diameter of the treated eyes showed a trend toward faster maximum dilatation in the AD groups, but change in pupillary measurements did not identify individuals with AD. CONCLUSIONS Pupillary response to dilute tropicamide did not effectively distinguish individual patients with AD from young or older control subjects.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009883 Ophthalmic Solutions Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. Eye Drop,Eyedrop,Eyedrops,Ophthalmic Solution,Eye Drops,Drop, Eye,Drops, Eye,Solution, Ophthalmic,Solutions, Ophthalmic
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D011680 Pupil The aperture in the iris through which light passes. Pupils
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
June 1996, Acta ophthalmologica Scandinavica,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
March 1997, Experimental neurology,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
March 1996, British journal of clinical pharmacology,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
October 2003, Neurobiology of aging,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
May 1997, The American journal of psychiatry,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
May 1988, Annals of internal medicine,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
February 1997, Archives of neurology,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
November 1968, American journal of ophthalmology,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
July 1997, Archives of neurology,
D N Loupe, and N J Newman, and R C Green, and M J Lynn, and K K WIlliams, and T C Geis, and H F Edelhauser
January 1999, Functional neurology,
Copied contents to your clipboard!